Assertio Holdings Inc
NASDAQ:ASRT

  • LAST PRICE
    0.9948
  • TODAY'S CHANGE (%)
    0.0602 (6.4413%)
  • Bid / Lots
    0.9900/ 42
  • Ask / Lots
    0.9984/ 2
  • Open / Previous Close
    0.9450 / 0.9346
  • Day Range
    0.9450
    0.9948
  • 52 Week Range
    0.7324
    6.5700
  • Volume
    588,247

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ASRT
Assertio Holdings Inc
94.6M
-0.3x
---
NAII
Natural Alternatives International Inc
40.0M
-11.4x
-18.19%
SCYX
SCYNEXIS Inc
91.2M
1.2x
---
AOBI
American Oriental Bioengineering Inc
30.0
0.0x
---
BVNRY
Bavarian Nordic A/S
2.1B
14.3x
---
TAK
Takeda Pharmaceutical Co Ltd
42.1B
46.1x
-8.01%
As of 2024-06-02

Company Information

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Contact Information

Headquarters
100 S. Saunders Road, Suite 300LAKE FOREST, IL, United States 60045
Phone
224-419-7106
Fax
302-636-5454

Executives

Independent Chairman of the Board
Peter Staple
Chief Executive Officer, Director
Brendan O'Grady
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Ajay Patel
Senior Vice President, General Counsel, Executive Officer
Sam Schlessinger
Senior Vice President and Chief Commercial Officer
Paul Schwichtenberg

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$94.6M
Revenue (TTM)
$142.1M
Shares Outstanding
95.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.92
EPS
$-3.95
Book Value
$1.46
P/E Ratio
-0.3x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-177.77%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.